Big Opportunity for EastGate’s Tiny Pill; Investors May have found a “Cure” to the Bear Market

 
NEW YORK - Nov. 2, 2014 - PRLog -- Investor News Source, a leading financial communications firm has initiated coverage on EastGate Acquisitions  (ESAQ).  Today the firm releases a report on the company and the nutraceutical/pharmaceutical industry and how it pertains to EastGate, its market opportunity, and its investment potential:

Whether it's a pill to ease our anxiety or a specially formulated beverage to help cut fat, people are buying health remedies now more than ever…and there's BIG MONEY to be made with emerging companies like tomorrow's pick.  Drugs today are more reliable, have less side effects and with FDA approval of a drug or compounds that make up a product, drug companies like my next pick are cashing in.

The global neutrocutical market is forecast to show growth in excess of 7% this year to reach almost $24 billion in 2015 according to research from Freedonia, the company that conducted the independent research report where I got these numbers... The study finds that the greatest growth will come from the sale of products that use ingredients with clinically confirmed health benefits. These compounds are used in a wide rang of dietary supplements, drinks, foods, and nutritional preparations for children and adults alike. Here is where things get interesting for tomorrow's pick... ESAQ.

EastGate's model is based on a multi-tiered approach that includes development of pharma-based products and innovative dietary supplements that are all approved by the FDA for use in their product. This is a big deal guy because it means that they are a market ready company that doesn't have too withstand the tedious FDA trial process.  Why is that?

Just to give you a little insight to the industry for both pharmaceutical products and natural supplements, they are developed using highly effective contemporary technologies and have demonstrated to be proven useful in improvement of bioavailability and biological action of incorporated molecules by combining pre-approved compunds. It's a mouth full I know but What that means is that ESAQ has developed ways for pharma and nutraceutical products to be more effective in treating specific ailments associated to diabetes for example, by providing a much faster and more efficient method in the delivery of the active ingredients with out needles. That's right, there are NO INJECTIONS. Their flag ship product is a sub-lingual tablet, that when taken three times a day, can stem the need for insulin injections. This is a revolutionary insulin replacement in the form a pill that you simply dissolve under your tongue.

Now think about this for a moment; Every day, over 5,000 adults and 25 children are diagnosed with diabetes.  Now at over 25 million the number of diabetics is expected to grow at an alarming rate.  Since it is a gateway to other far-reaching diseases the treatment alone for diabetes accounts for 1/3 of all Medicare spending and as many as 1 in 3 American adults will have diabetes in 2050 if present trends continue.

The benefit of the ESAQ product, besides being non invasive, is that the tablet dissolves in 3-5 minutes, which allows for quick onset of the medication to start working.  To diabetics a pill like this would be life changing because both diabetics and pre-diabetics tend to avoid injection needles if they are symptomless. No one wants to prick their finger 6 times a day to check their blood sugar and certainly no one wants to have multiple injections with a one inch needle, each and every day of their life.  If you're a person who endures this on a daily basis then you know exactly what I'm talking about and for me this is personal because my father has diabetes so I know all too well what he goes through.

Recently the company announced that it has entered into an agreement with Purine Pharma, LLC (www.purinepharma.com) for licensing, manufacturing, marketing, and distributing ESAQ's nutraceutical line of products. Purine Pharma, LLC supplies and distributes liquid and dose over the counter pharmaceuticals as well as drugs, which need a prescription. With over 200 products in their line, Purine has products that range from cold & allergy medicine to topical and vitamin supplements.

ESAQ holds a ground breaking solution for an industry that up until this point has had the majority of its customers get used to the idea of sticking themselves with needles and there is HUGE opportunity in this space to participate in joint ventures or simply be acquired. In fact, diabetes testing solutions companies have been primed for acquisition by much larger companies and it's not to the tune of small numbers either:

ESAQ's Anna Gluskin, CEO and Chairman was also recently interviewed on IntelRadio (Click Here to listen to this interview) where she explained the goal for Eastgate and focused on ESAQ's revolutionary, non-invasive sublingual insulin tablet for effectively dealing with diabetes in a non-invasive format. I suggest every one listen to this interview which is linked above.

         "Our agreement with Purine Pharma solidifies the company's progression to commercialization" says Anna Gluskin , EastGate's CEO. "Opening up the distribution channels for our innovative product line utilizing our sub-micron platform technology, this will reinforce our technology, expand our product line and build a revenue stream for the company."

Let's speculate here for a moment;

PDL BioPharma, Inc. acquired the rights to receive royalties and milestones payable on sales of Type 2 diabetes products licensed by Depomed in exchange for a $240.5 million cash payment.

Johnson & Johnson agreed to acquire Inverness Medical Technology Inc. 's diabetes-care-products business for about $1.3 billion.

AstraZeneca will pay $2.7 billion upfront and as much as $1.4 billion more to Bristol-Myers Squibb Co. for its diabetes-treatment business depending on regulatory, commercial and sales goals.

Carlyle Group LP agreed to buy the Ortho Clinical unit of Johnson & Johnson for $4.15 billion, a deal that would shed the health-care products company's only diagnostics division noting that the company's diabetes business "may be the target of future strategic alternatives."


If you take a deeper look into the company's developing product line you'll find.....
.....The team at Investor News Source offers a free subscription service to receive exclusive reports and articles on emerging companies in the OTC.  You can sign up via the following link to finish reading the rest of this ESAQ report and start receiving your own updates:

http://www.investornewssource.com

Disclaimer can be found here: http://www.investornewssource.com
End
Email:***@investornewssource.com Email Verified
Tags:Diabetes Medicine, Diabetes, ESAQ, EastGate Pharmaceutical, Anna Gluskin
Industry:Health, Investment
Location:New York City - New York - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
INS Consulting PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share